Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
Castle Biosciences (Nasdaq: CSTL), a healthcare company specializing in innovative diagnostic tests, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's executive management will deliver a corporate overview on Wednesday, Dec. 4, 2024, at 10:50 a.m. Eastern time.
A live audio webcast of the presentation will be accessible through Castle Biosciences' investor relations website. Additionally, a replay of the presentation will be made available after the live broadcast concludes.
Castle Biosciences (Nasdaq: CSTL), un'azienda sanitaria specializzata in test diagnostici innovativi, ha annunciato la sua partecipazione alla 36ª Conferenza Annuale sulla Sanità di Piper Sandler. Il management esecutivo dell'azienda presenterà una panoramica aziendale mercoledì 4 dicembre 2024, alle 10:50 (ora dell'Est).
Un webcast audio in diretta della presentazione sarà accessibile attraverso il sito web per le relazioni con gli investitori di Castle Biosciences. Inoltre, una registrazione della presentazione sarà disponibile dopo la conclusione della trasmissione dal vivo.
Castle Biosciences (Nasdaq: CSTL), una empresa de atención médica especializada en pruebas diagnósticas innovadoras, ha anunciado su participación en la 36ª Conferencia Anual de Atención Médica de Piper Sandler. La dirección ejecutiva de la empresa presentará un resumen corporativo el miércoles 4 de diciembre de 2024, a las 10:50 a.m., hora del Este.
Una transmisión de audio en vivo de la presentación estará accesible a través del sitio web de relaciones con inversores de Castle Biosciences. Además, se hará disponible una repetición de la presentación después de que concluya la transmisión en vivo.
캐슬 바이오사이언스(Castle Biosciences, Nasdaq: CSTL)는 혁신적인 진단 테스트를 전문으로 하는 건강 관리 회사로, 파이퍼 샌들러 제36회 연례 의료 회의에 참여한다고 발표했습니다. 회사의 경영진은 2024년 12월 4일 수요일 오전 10:50 동부 표준시에 기업 개요를 발표할 예정입니다.
발표의 실시간 오디오 웹캐스트는 캐슬 바이오사이언스의 투자자 관계 웹사이트를 통해 접근할 수 있습니다. 또한, 생중계가 끝난 후 발표의 재방송도 제공될 것입니다.
Castle Biosciences (Nasdaq: CSTL), une entreprise de santé spécialisée dans les tests diagnostiques innovants, a annoncé sa participation à la 36ème Conférence Annuelle sur la Santé de Piper Sandler. La direction exécutive de l'entreprise présentera un aperçu de la société mercredi 4 décembre 2024, à 10h50, heure de l'Est.
Un webcast audio en direct de la présentation sera accessible via le site web des relations investisseurs de Castle Biosciences. De plus, un enregistrement de la présentation sera mis à disposition après la conclusion de la diffusion en direct.
Castle Biosciences (Nasdaq: CSTL), ein Gesundheitsunternehmen, das sich auf innovative diagnostische Tests spezialisiert hat, hat seine Teilnahme an der 36. jährlichen Gesundheitskonferenz von Piper Sandler bekannt gegeben. Das Management des Unternehmens wird am Mittwoch, den 4. Dezember 2024, um 10:50 Uhr Eastern Time einen Unternehmensüberblick geben.
Ein Live-Audio-Webcast der Präsentation wird über die Investor-Relations-Website von Castle Biosciences zugänglich sein. Darüber hinaus wird eine Wiederholung der Präsentation nach Abschluss der Live-Übertragung verfügbar sein.
- None.
- None.
A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx. A replay of the webcast will be available following the conclusion of the live broadcast.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241120391522/en/
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
FAQ
When is Castle Biosciences (CSTL) presenting at the Piper Sandler Healthcare Conference 2024?
How can I watch Castle Biosciences' (CSTL) presentation at the Piper Sandler Conference?
Will there be a replay available of Castle Biosciences' (CSTL) Piper Sandler Conference presentation?
